NeoGenomics Industry Overview and Competitive Landscape

NeoGenomics is a leading provider of molecular diagnostics and genomic testing services. They offer a wide range of tests, including next-generation sequencing, fluorescence in situ hybridization, and cytogenetics.

Their industry is highly competitive, with several other companies offering similar services. NeoGenomics has managed to carve out a niche for itself through its focus on providing high-quality, cost-effective testing solutions.

The company has a strong presence in the US market, with a network of laboratories and testing facilities across the country. This allows them to quickly and efficiently process samples and deliver results to healthcare providers.

NeoGenomics has also made significant investments in its technology and infrastructure, including the development of its proprietary testing platforms. This has enabled the company to stay at the forefront of the industry and provide cutting-edge testing solutions to its customers.

On a similar theme: Correctional Services Corporation

NeoGenomics is a leader in cancer genomics and information services. They offer a range of financial products and services to help patients and healthcare providers manage the cost of cancer care.

Their financial information is transparent and accessible, with detailed billing and insurance information available online. This helps patients understand their costs and plan their care accordingly.

NeoGenomics also participates in various insurance programs, including Medicare and Medicaid, to ensure that patients have access to their services regardless of their financial situation.

For your interest: CTBC Financial Holding

The financial highlights of any company or individual are a key indicator of their overall financial health. In the past year, our company's revenue has increased by 25% due to a successful marketing campaign.

This growth in revenue has led to a significant increase in our profit margin, from 10% to 15%. The extra funds have been reinvested into the business, allowing us to expand our product line and hire more staff.

One notable expense has been the cost of upgrading our technology infrastructure, which has risen by 30% due to the need for more robust and secure systems. Despite this, our operating costs have remained relatively stable.

The financial stability has allowed us to pay off debts and build a cash reserve, providing a cushion against any future economic downturns.

Additional reading: Raymond James Financial

Analyst recommendations can be a crucial factor in deciding whether to invest in a particular company.

NeoGenomics, Inc. has received various analyst recommendations, with BTIG Research downgrading the company to Neutral from Buy on July 30.

On July 18, BofA Securities adjusted NeoGenomics' price target to $8 from $10 while maintaining a Neutral rating.

Guggenheim initiated coverage on NeoGenomics with a Neutral rating on May 15.

Leerink Partners downgraded NeoGenomics to Market Perform from Outperform on April 30, lowering the price target to $9 from $25.

Needham cut NeoGenomics' price target to $8.50 from $18 on April 29, but maintained a Buy rating.

Here are the analyst recommendations for NeoGenomics, Inc.:

Understanding ICT spending is crucial for making informed business decisions. IT Client Prospector provides intelligence on a company's likely spend across technology areas, enabling you to grasp their digital strategy.

NeoGenomics Inc's ICT spend is likely to be significant, as IT Client Prospector offers insights that can help you anticipate their technology investments.

A different take: Trump Media & Technology Group

NEOGENOMICS INC has had a consistent Investment Rating of SELL across multiple reports from Argus.

The target price for NEOGENOMICS INC has been decreasing over the past few weeks, with the latest report suggesting a target price of $9.000000, a $2.000000 increase from the previous report.

NEOGENOMICS INC's Industry Subrating has remained Medium across all reports.

The company's Management Subrating has been consistently Low.

NEOGENOMICS INC's Safety Subrating has also been Low across all reports.

The Financial Strength Subrating has been Medium in the most recent report, but was Low in the previous report.

The Growth Subrating for NEOGENOMICS INC has been Low in all reports.

The Value Subrating has been Medium in the most recent report, but was High in the report from 23 days ago.

Here's a summary of the Investment Ratings and target prices for NEOGENOMICS INC:

NeoGenomics has been making waves in the industry with its recent announcements and updates.

The company is set to highlight its Radar ST MRD Assay at the ESMO Congress 2025, which is scheduled to take place on an unspecified date.

NeoGenomics has appointed Chris Smith as its new CEO, effective September 11, 2025. This move marks a significant change in leadership for the company.

The health care sector has seen a decline in stocks premarket on Friday, August 29, 2025, according to a sector update.

Here are some key events related to NeoGenomics:

NeoGenomics has also seen changes in its leadership, with Elizabeth Floegel resigning from the board of directors, effective August 5, 2025.

The company has been involved in patent litigation with Natera, with the court deciding to invalidate Natera's asserted patents on August 29, 2025.

NeoGenomics is set to report its third-quarter 2025 financial results on October 28, 2025, according to a press release.

NeoGenomics has some notable competitors in the market. They are all public companies, just like NeoGenomics.

The number of employees at these competitors varies greatly, with Quest Diagnostics Inc having the largest workforce with 45,000 employees. In contrast, NeoGenomics has around 2,200 employees.

Here's a brief comparison of the competitors' headquarters locations:

Industry analytics is a crucial aspect of competitive analysis. It helps businesses understand their position in the market and identify areas for improvement.

Analyzing industry trends can reveal opportunities for growth, such as the increasing demand for eco-friendly products, which has led to a 20% growth in sales for companies that have adapted to this trend.

Industry benchmarks provide a standard against which businesses can measure their performance, like the average customer acquisition cost of $50 in the tech industry, which can help businesses determine if their own costs are in line.

By using industry analytics, businesses can gain insights into their competitors' strategies, such as the 30% increase in social media advertising seen in the retail industry, which can inform their own marketing decisions.

Industry analytics can also help businesses identify emerging trends and technologies, like the growing use of artificial intelligence in customer service, which can provide a competitive edge.

Let's take a look at the key parameters of our competitors in the industry. NeoGenomics Inc is a public company based in the United States of America, specifically in Fort Myers, Florida.

Their headquarters is located in Fort Myers, Florida, and they have a significant number of employees, with 2,200 people working for the company.

Quest Diagnostics Inc is another public company, also based in the United States of America, with its headquarters in Secaucus, New Jersey. They have a much larger workforce, with 45,000 employees.

Here's a comparison of the key parameters of our competitors:

These numbers give us a better understanding of the size and scale of our competitors in the industry.